CellaVision AB
OTC:CLVSF
CellaVision AB
OTC:CLVSF
Price:
15.85
USD
Market Cap:
$378m
Relative Value
The Relative Value of one
CLVSF
stock under the Base Case scenario is
28.18
USD.
Compared to the current market price of 15.85 USD,
CellaVision AB
is
Undervalued by 44%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
CLVSF
Relative Value
Base Case
28.18
USD
Undervaluation 44%
Multiples Across Competitors
CLVSF Competitors Multiples
CellaVision AB Competitors
CellaVision AB Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| SE |
|
CellaVision AB
OTC:CLVSF
|
3.6B USD | 4.7 | 23.2 | 16.7 | 16.7 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
199.8B USD | 4.5 | 30.7 | 17.6 | 24.2 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
176.1B USD | 17.4 | 61.3 | 46.5 | 57.2 | |
| US |
|
Stryker Corp
NYSE:SYK
|
148.2B USD | 5.9 | 45.4 | 22.9 | 27.7 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
124.9B USD | 3.5 | 27.1 | 14.7 | 21.5 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
112.5B USD | 5.6 | 38.9 | 22.7 | 30.5 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
46.7B EUR | 2 | 22.1 | 12.2 | 17.2 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
51B USD | 11.8 | 47.9 | 34 | 37.6 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
49.5B USD | 2.3 | 28.2 | 10.9 | 18.4 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
50.2B USD | 8.2 | 46.5 | 25.6 | 28.1 | |
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
38.4B USD | 1.8 | 17.9 | 12.7 | 15.3 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
